Immuron Executes U.S. Travelan Sales Agreement With Medico-Mart, Inc.

MELBOURNE, Australia, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that the Company has executed a non-exclusive distribution agreement with Medico-Mart, Inc. of Waukesha, Wisconsin.  The terms and conditions of the agreement will remain confidential.

Medico-Mart, Inc. specializes in fulfilling the product needs of physician offices, clinics, and healthcare organizations throughout the U.S.

Medico-Mart was founded in 1935 and is now a leading distribution healthcare company in the U.S. servicing customers across a wide variety of specialist areas including: pediatrics, internal medicine, family practice, travel medicine, and occupational medicine. Their coverage ranges from single physician offices to large healthcare organizations.

Jerry Walsh, President of Medico-Mart, said;

“The introduction of Travelan into our pharmaceutical portfolio will allow us to better serve our travel medicine customers whilst providing Medico-Mart with opportunities for additional business development in the travel market.  We look forward to a successful partnership with Immuron.”

Thomas Liquard, CEO of Immuron added;

“Since its creation more than 70 years ago, Medico-Mart has always been at the forefront of the travel medicine market.  We are thrilled to add Medico-Mart, a company that clearly understands the value of differentiated travel products like Travelan, to our growing list of partners in the U.S.”

About Immuron

Immuron Ltd (ASX:IMC; (OTCQB:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit:

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.


Contact Data